サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514033

免疫グロブリン静注（IVIg）の世界市場

Intravenous Immunoglobulin (IVIg)

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
免疫グロブリン静注（IVIg）の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

免疫グロブリン静注（IVIg）の世界市場は2030年までに340億米ドルに達する見込み

2023年に191億米ドルと推定される免疫グロブリン静注（IVIg）の世界市場は、分析期間2023-2030年にCAGR 8.6%で成長し、2030年には340億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるIgAは、CAGR 10.7%を記録し、分析期間終了までに137億米ドルに達すると予想されます。IgEセグメントの成長率は、分析期間中CAGR 7.8%と推定されます。

米国市場は51億米ドルと推定される一方、中国はCAGR 8.0％で成長すると予測される

米国の免疫グロブリン静注（IVIg）市場は2023年に51億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに52億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.0％と7.0％と予測されています。欧州では、ドイツがCAGR約6.4%で成長すると予測されています。

世界の免疫グロブリン静注（IVIg）市場- 主要動向と促進要因のまとめ

免疫グロブリン静注（IVIg）は治療において重要な成分であり、免疫防御が不十分な人々に必要な抗体を提供します。何千人ものドナーの血漿から得られるIVIGには、様々な病原体と闘うために不可欠な抗体が豊富に含まれており、免疫不全症の患者にとって不可欠なものとなっています。体内に必要な抗体を補充することで、IVIGは多くの感染症に対する強固な防御を提供し、体内で十分な抗体を産生できない患者さんにとって極めて重要です。さらに、IVIGは自己免疫疾患の治療にも重要な役割を果たしています。自己免疫疾患とは、体の免疫システムが誤って自分自身の細胞を攻撃してしまう病気です。高濃度の抗体を投与することで、IVIGはこの誤った免疫反応を緩和し、免疫性血小板減少症や自己免疫性溶血性貧血などの症状を緩和します。

IVIGの投与は通常、臨床の場で静脈内に行われ、投与量と投与頻度は患者さん固有の医療ニーズと体重に合わせて綿密に調整されます。このような個別化アプローチにより、患者さんは副作用を最小限に抑えながら最適な治療効果を得ることができます。しかし、IVIG療法には頭痛や疲労などの軽度の症状からアレルギー反応などの重篤な症状まで、さまざまな副作用が伴う可能性があるため、医療従事者による注意深いモニタリングと、これらの副作用を軽減するための事前の対策が必要となります。最近の動向では、皮下投与に代わる薬剤の開発や、抗炎症作用が強化された誘導体であるM254のような技術革新が見られ、特に自己免疫疾患に対して、従来のIVIGよりも強力で忍容性の高い治療選択肢を提供することが臨床試験で期待されています。

IVIGの需要は、その多様な医療用途、希少疾患の治療における有効性、慢性疾患の早期介入や維持療法における使用の増加によって牽引されています。IVIG製造における技術の進歩により、IVIGの安全性と拡張性が向上し、副作用が軽減され、患者の全体的な忍容性が改善されています。さらに、世界ヘルス活動や免疫学専門センターがIVIGを国の治療ガイドラインに組み込み、その使用を促進しています。患者アドボカシーと教育により、この不可欠な治療へのアクセスを求める患者が増え、需要はさらに高まっています。規制当局の支援、特に希少疾病用医薬品に対する支援はIVIGの利用を促進し、既存市場でも新興市場でもこの重要な治療薬へのアクセスを向上させています。これらの要因は、現代ヘルスケアにおけるIVIGの重要性の高まりを裏付けるものであり、世界の医療現場における役割の拡大と採用の拡大を示唆しています。

調査対象企業の例（注目の24社）

  • Bharat Serums and Vaccines Limited
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire plc
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-7776

Global Intravenous Immunoglobulin (IVIg) Market to Reach US$34.0 Billion by 2030

The global market for Intravenous Immunoglobulin (IVIg) estimated at US$19.1 Billion in the year 2023, is expected to reach US$34.0 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. IgA, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$13.7 Billion by the end of the analysis period. Growth in the IgE segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 8.0% CAGR

The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Intravenous Immunoglobulin (IVIg) Market - Key Trends and Drivers Summarized

Intravenous Immunoglobulin (IVIG) is a critical component in medical treatments, providing necessary antibodies to those with inadequate immune defenses. Derived from the plasma of thousands of donors, IVIG encompasses a wide array of antibodies essential for combating various pathogens, making it indispensable for individuals with immunodeficiency disorders. By supplementing the body's antibody requirement, IVIG offers robust protection against a multitude of infections, crucial for patients whose bodies cannot produce sufficient antibodies. Additionally, IVIG plays a significant role in treating autoimmune diseases, where the body's immune system erroneously attacks its own cells. By introducing a high concentration of antibodies, IVIG helps mitigate this misguided immune response, offering relief for conditions such as immune thrombocytopenia and autoimmune hemolytic anemia, among others.

The administration of IVIG is generally carried out intravenously in a clinical setting, where the dosage and frequency are meticulously tailored to the patient's specific medical needs and body weight. This personalized approach ensures that patients receive optimal treatment effectiveness with minimized side effects. However, IVIG therapy can be accompanied by adverse reactions ranging from mild symptoms like headaches and fatigue to more severe conditions such as allergic reactions, necessitating careful monitoring and preemptive measures by healthcare providers to mitigate these effects. Recent advancements have seen the development of subcutaneous alternatives and innovations like M254, a derivative with enhanced anti-inflammatory properties, showing promise in clinical trials for providing a more potent and better-tolerated treatment option than traditional IVIG, particularly for autoimmune conditions.

The demand for IVIG is driven by its diverse medical applications, effectiveness in treating rare diseases, and its increasing use in early intervention and maintenance therapy for chronic conditions. Technological advancements in IVIG production have enhanced its safety and scalability, reducing side effects and improving overall tolerability for patients. Additionally, global health initiatives and specialized immunology centers have integrated IVIG into national treatment guidelines, promoting its use. Patient advocacy and education have further increased demand, as more patients seek access to this essential treatment. Regulatory support, particularly for orphan drugs, has expedited the availability of IVIG, enhancing access to this crucial medication in both established and emerging markets. These factors collectively underscore the growing importance of IVIG in modern healthcare, pointing towards an expanded role and increased adoption in medical settings globally.

Select Competitors (Total 24 Featured) -

  • Bharat Serums and Vaccines Limited
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire plc
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Intravenous Immunoglobulin (IVIg) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Autoimmune Diseases Boosts Demand for IVIg Treatments
    • Advances in Extraction and Processing Technologies Improve IVIg Safety and Efficacy
    • Growing Geriatric Population Amplifies Need for Immunoglobulin Therapies
    • Expansion of Therapeutic Applications Beyond Immunodeficiency to Neurology
    • Rising Awareness and Diagnosis Rates of Rare Diseases Propel IVIg Usage
    • Shift Toward Home Care and Self-Administration Trends Enhance Patient Compliance
    • Advancements in Personalized Medicine Tailor IVIg Therapies to Individual Needs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Intravenous Immunoglobulin (IVIg) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for IgA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for IgE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for IgG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for IgM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for IgD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • JAPAN
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • CHINA
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • EUROPE
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • FRANCE
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • GERMANY
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030

IV. COMPETITION